NASDAQ · Health care

Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia Pharmaceuticals Inc. brought in $311.5M of revenue over the twelve months to June 30, 2026, up 19.8% from a year earlier. Net income was $314.1M, a net margin of 100.8%. At June 30, 2026 it held $179.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Revenue (last 12 months)

$311.5M

+19.8% year on year

Net margin

100.8%

What Aurinia Pharmaceuticals Inc. does

Aurinia Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AUPH.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$283.1M	$104.9M	$287.2M	$2.07	n/a
2024	$235.1M	-$4.7M	$5.8M	$0.04	n/a
2023	$175.5M	-$91.7M	-$78M	-$0.54	n/a
2022	$134M	-$111.5M	-$108.2M	-$0.76	n/a
2021	$45.6M	-$180.7M	-$181M	-$1.40	n/a
2020	$50.1M	-$104.3M	-$102.7M	-$0.87	n/a

Latest SEC filings

What Aurinia Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 26, 2026
Activist stake changed SCHEDULE 13D/A
August 19, 2026
Other event 8-K
August 6, 2026
Quarterly report 10-Q · period to June 30, 2026
August 6, 2026
Quarterly results 8-K
June 4, 2026
Activist stake changed SCHEDULE 13D/A
June 4, 2026
Shareholder vote results 8-K
May 11, 2026
Acquisition or sale completed 8-K
May 11, 2026
Tender offer (amended) SC TO-T/A
May 7, 2026
Quarterly report 10-Q · period to March 31, 2026
May 7, 2026
Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 11, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about AUPH

What does Aurinia Pharmaceuticals Inc. do?

Aurinia Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AUPH.

Is Aurinia Pharmaceuticals Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $314.1M on revenue of $311.5M, a net margin of 100.8%.

How much revenue does Aurinia Pharmaceuticals Inc. make?

Over the twelve months to June 30, 2026 Aurinia Pharmaceuticals Inc. reported revenue of $311.5M. That is 19.8% more than a year earlier.

When did Aurinia Pharmaceuticals Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 11, 2026.

Similar companies

Follow AUPH

Get an email when Aurinia Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow AUPH: get an email when it files

Where the numbers come from

Financial figures are the values Aurinia Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.